Company Overview of Rani Therapeutics, LLC
Rani Therapeutics, LLC develops oral biotherapeutics technologies for the oral delivery of large drug molecules that include peptides, proteins, and antibodies. It offers TNFa Inhibitors that are used for treatment of inflammatory disorders, including rheumatoid arthritis and Crohn's disease; Parathyroid Hormone for the treatment of osteoporosis; Human Growth Hormone, a peptide hormone that stimulates growth, cell reproduction, and regeneration, as well as is used in the treatment of growth disorders and growth deficiency; and Somatostatin, a growth hormone-inhibiting hormone that is used to treat various indications, including enteroendocrine tumors (in the stomach, intestine, or pancreas),...
2051 Ringwood Avenue
San Jose, CA 95131
Founded in 2012
Key Executives for Rani Therapeutics, LLC
Chairman and Chief Executive Officer
Vice President of Operations
Vice President of Business Development
Vice President of Research & Development
Compensation as of Fiscal Year 2017.
Rani Therapeutics, LLC Key Developments
Dennis Ausiello Joins Board Of Directors For Rani Therapeutics
Jun 13 18
Rani Therapeutics announced that Dennis (Denny) Ausiello, M.D. has joined its Board of Directors. Dr. Ausiello is a nationally recognized leader in academic medicine, elected to the National Academy of Medicine in 1999 and the American Academy of Arts and Sciences in 2003. He previously served as Chief of Medicine at Massachusetts General Hospital from 1996 until 2013. In this role, he led one of the strongest departments of medicine in the country. Currently the Director of the Center for Assessment Technology and Continuous Health (CATCH), Dr. Ausiello founded this program as a joint effort between Massachusetts General Hospital and Massachusetts Institute of Technology (MIT) physicians, scientists and engineers to provide real-time measurement and analysis of the human phenotype in wellness and disease.
Rani Therapeutics Appoints Dr. Rodolphe Ruffy as First Medical Director
May 30 18
Rani Therapeutics announced that Rodolphe Ruffy, M.D. has joined the company as medical director. Dr. Ruffy brings decades of experience as a practicing physician, including more than 20 years in American academic medicine. In his new role, Dr. Ruffy will be responsible for the company's scientific outreach strategy, including leading the creation and publishing of scientific papers and establishing a Scientific Advisory Board for Rani. Previously, Dr. Ruffy held tenured Professor of Medicine positions at Washington University and the University of Utah.
Shire plc and Rani Therapeutics, LLC Enter into Collaboration to Evaluate Use of the Rani Pill Technology for the Oral Delivery of Factor Therapy
Dec 5 17
Shire plc and Rani Therapeutics announced a collaboration to exclusively conduct research on the use of the Rani Pill(TM) technology for the oral delivery of factor VIII (FVIII) therapy for patients with hemophilia A. The collaboration agreement grants Shire an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following completion of feasibility studies. As part of the collaboration, Shire has also made an equity investment into Rani Therapeutics. Rani Therapeutics has developed a novel approach for the oral delivery of large molecules, including peptides, proteins, and antibodies, using the Rani Pill, a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall. Since the intestines do not have sharp pain receptors, the intestinal delivery is expected to be pain free.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 5, 2017
August 24, 2017